Vaccines against Covid-19 have become a product ‘best seller‘. It was in December 2020 when the first doses began to be distributed. A few months later, the first forecasts of income that pharmaceutical companies would have for their antigens were known, which, over time, have been increasing. To such an extent that in 2022 will exceed 74,800 million euros.
That supposes a 29% growth if we compare it with the estimated sales figure for these antigens in 2021, which will be around 57.8 billion euros, according to Airfinity forecasts.
The market for vaccines against Covid will be dominated by those that use the technology of the messenger RNA. That is, those developed by Pfizer/BioNTech and Moderna. Countries are only using these vaccines to administer booster doses, which is why Airfinity forecasts that they will be the highest revenue generators.
As we have already been telling in EL ESPAÑOL-Invertia, the vaccine for Pfizer/BioNTech it is the one that has generated the most revenue in 2021 and will continue to do so in 2022. It will even dominate the pharmaceutical market, thus unseating Humira, the AbbVie drug that is used to treat different pathologies of the immune system, from the first place of ‘best-selling’ drugs.
According to the figures published by Airfinity, this antigen will reach sales worth 37,660 million euros in 2022. In fact, it will monopolize 50% of the market share of coronavirus vaccines, although it is a lower figure than it had in 2021 (57%)
It will be followed by the preparation of modern, with just over 22,560 million euros and a market share of 30%. In the case of this pharmaceutical vaccine, its share will increase from the 26% that the 2021 forecasts had set.
Airfinity Research Director Claus Johansen explained that “there has been a growing demand for mRNA vaccines throughout 2021 and this is likely to continue. Technology will also benefit because it makes it easier to adapt vaccines to the different variants of Covid that appear. Thus, we estimate that Pfizer and Moderna will sell 5.4 billion doses this year, but global demand is much higher“.
Novavax will overtake AstraZeneca and Janssen
Well below the sales figures for messenger RNA vaccines is the antigen of AstraZeneca and the University of Oxford: in 2022 it will be close to 3,790 million euros. Talking about Janssenits single-dose vaccine will achieve sales worth 3,084 million euros in 2022. As for its market share, this will be 4%, one point below that of AstraZeneca.
And the last to join the arsenal, that of Novavax, will exceed 4,050 million euros, placing it above the AstraZeneca and Janssen antigens. It should be remembered that it was in December when the European Medicines Agency authorized this antigen.
In its report, Airfinity warns of a increase in the prices of messenger RNA vaccines. “MRNA vaccines and a possible omicron-targeted vaccine are expected to generate higher prices in 2022,” they explain.
To which they add: “As the world moves from a pandemic to a endemicall producers are expected to increase prices.”